文献速递脑血管病神经重症与神经感染

急性卒中静脉硫酸镁疗效的荟萃分析

Intravenous Magnesium Sulfate in Acute Stroke.
PubMed 文献 · Stroke · 2019-01-01

该荟萃分析纳入7项随机对照试验共4347例患者,评估急性卒中后静脉给予硫酸镁对90天全局结局、功能结局和死亡率的影响。总体结果显示硫酸镁未改善功能结局、全局结局或死亡率;仅在缺血性卒中亚组中观察到改良Rankin量表评分降低,但作者提醒需极度谨慎解读。

要点

  • 静脉硫酸镁总体上未改善急性卒中患者90天功能结局、全局结局或死亡率。
  • 仅在缺血性卒中亚组中观察到改良Rankin量表评分降低,但证据有限。
  • 该亚组结果需谨慎解读,因纳入患者数量有限。

核心结论

  • 静脉硫酸镁总体上未改善急性卒中(缺血性和非缺血性)后90天的全局结局、功能结局和死亡率。
  • 仅在缺血性卒中亚组中观察到全局结局改善,但作者提醒因亚组患者数量有限需极度谨慎解读。

研究设计与样本

  • 系统综述与荟萃分析,检索Pubmed、Science Direct、CENTRAL和ClinicalTrials.gov至2017年11月11日。
  • 纳入7项随机对照试验,共4347例患者。
  • 采用随机效应模型、加权均数差、标准化均数差和比值比合成结果。

主要发现

  • 与安慰剂相比,硫酸镁未改善90天Barthel指数>60的功能结局(OR=1.05;95%CI 0.92-1.19)。
  • 硫酸镁未改善90天Barthel指数>95的功能结局(OR=0.95;95%CI 0.76-1.20)。
  • 硫酸镁未改善90天改良Rankin量表评估的全局结局(SMD=-0.01;95%CI -0.12至0.10)。
  • 在仅纳入缺血性卒中患者的亚组荟萃分析中,静脉硫酸镁降低90天改良Rankin量表评分(WMD=-0.96;95%CI -1.34至-0.58;I2=0%)。
  • 死亡率未改变(OR=1.10;95%CI 0.94-1.29)。

临床怎么用

  • 不推荐常规使用静脉硫酸镁改善急性卒中患者90天功能结局或降低死亡率。
  • 缺血性卒中亚组的获益信号需进一步研究验证,不应据此改变临床实践。

局限性

  • 缺血性卒中亚组分析纳入患者数量有限,结果需极度谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Acute stroke treatment is challenging, and stroke remains a major cause of death and disability. The purpose of this meta-analysis is to investigate the effects of postacute stroke intravenous administration of the neuroprotectant magnesium sulfate (MgSO4) on global outcome, functional outcome, and mortality 90 days poststroke (ischemic and nonischemic). Methods- We searched in Pubmed, Science Direct, CENTRAL, and ClinicalTrials.gov, up to November 11, 2017, and we conducted a systematic review and meta-analysis of randomized controlled trials. We synthesized results by using random-effects model, weighted mean differences, standardized mean differences, and odds ratios. Results- Seven randomized controlled trials (4347 patients) met our criteria. Compared with placebo, treatment did not improve functional outcome defined as Barthel Index >60 (odds ratio =1.05; 95% CI, 0.92-1.19) and >95 (odds ratio =0.95; 95% CI, 0.76-1.20), 90 days poststroke. It also did not improve global outcome measured with modified Rankin Scale (standardized mean difference =-0.01; 95% CI, -0.12 to 0.10), 90 days poststroke. In an additional subgroup meta-analysis that exclusively included ischemic stroke patients, intravenous MgSO4 resulted in lower modified Rankin Scale score (improved global outcome; weighted mean difference =-0.96; 95% CI, -1.34 to -0.58; I2=0%], 90 days poststroke. Finally, mortality stayed unaltered (odds ratio =1.10; 95% CI, 0.94-1.29). Conclusions- The findings of our meta-analysis showed that intravenous MgSO4 generally did not improve global/functional outcomes and mortality at 90 days after stroke (combined ischemic stroke and nonischemic stroke). The finding of favorable neurological outcome, selectively in ischemic stroke patients, should be viewed with extreme caution given the limited number of patients included in this subgroup meta-analysis.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Avgerinos KI, Chatzisotiriou A, Haidich AB, et al. Intravenous Magnesium Sulfate in Acute Stroke. Stroke. 2019. PMID: 30852968. doi:10.1161/STROKEAHA.118.021916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。